FDA Greenlights First Drug for ESR1-Mutated Breast Cancer

[MEDPAGE TODAY]( Oncology Update Tuesday, January 31, 2023 [FDA Greenlights First Drug for ESR1-Mutated Breast Cancer]( [Reversible BTK Inhibitor Gets FDA Nod for Mantle Cell Lymphoma]( [JAK Inhibitor Improves Symptoms, Anemia in Myelofibrosis]( [Analysis of ctDNA Pinpoints Responders to Second-Line GIST Therapy]( ADVERTISEMENT Exclusives & Features [Video of Pfizer Employee Explaining COVID Vaccine Research Debunked]( [Med Schools Withdraw from U.S. News List, but Say Hospital Rankings Are Separate]( [Plan for More Oversight of Pathogen-Related Research Passes Hurdle]( [Open-label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies.]( Anemia is a common side effect of myelosuppressive chemotherapy; however, chemotherapy-induced anemia (CIA) management options are suboptimal. We evaluated the efficacy and safety of roxadustat in... [READ MORE]( [Personalising Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer: Protocols for the International Phase III FOxTROT2 and FOxTROT3 Randomised-Controlled Trials.]( AIM: FOxTROT1 established a new standard of care for managing locally advanced colon cancer (CC) with neoadjuvant chemotherapy (NAC). Six weeks of neoadjuvant oxaliplatin and fluoropyrimidine (OxFp)... [READ MORE]( [Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.]( Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy can provide durable remission in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after failure of chemoimmunotherapy.... [READ MORE]( [Racial and Ethnic Differences in Sickle Cell Disease within the United States: From Demographics to Outcomes.]( INTRODUCTION: Sickle cell disease mainly affects African Americans, and studies on racial differences in sickle cell disease outcomes are scanty. This study examined racial and ethnic differences in... [READ MORE]( [Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.]( BACKGROUND: The aim of this study was to develop a prognostic model for survival in older/unfit patients with newly diagnosed acute myeloid leukemia (AML) who were treated with lower-intensity... [READ MORE]( [A Property of Everyday Health group]( © 2023 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Spec_Oncology_Update?xid=nl_mpt_Oncology_update_2023-01-31&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 345 Hudson Street 16th Floor New York, NY 10014